Halia Therapeutics, a US-based clinical-stage biotechnology company, announced on Wednesday that it has dosed its first participant in a Phase 1 clinical study with HT-6184, a novel small molecule inhibitor of NEK7 and the NLRP3 pathway.
HT-6184 is the lead molecule from the company's structure-based drug design strategy that has developed a range of novel drug candidates aimed at essential mediators of inflammation with the potential to treat various diseases, including heart disease, Alzheimer's and Parkinson's disease, many cancers, fatty liver diseases, inflammatory bowel disorders, and other conditions linked to chronic inflammation.
The Phase 1 trial, a single-centre, randomised, placebo-controlled, single ascending dose study, is intended to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HT-6184 in up to 32 healthy human subjects.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007